KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Operating Leases (2022 - 2025)

Historic Operating Leases for Recursion Pharmaceuticals (RXRX) over the last 4 years, with Q3 2025 value amounting to $50.0 million.

  • Recursion Pharmaceuticals' Operating Leases fell 4412.53% to $50.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $50.0 million, marking a year-over-year decrease of 4412.53%. This contributed to the annual value of $67.2 million for FY2024, which is 3577.63% up from last year.
  • Recursion Pharmaceuticals' Operating Leases amounted to $50.0 million in Q3 2025, which was down 4412.53% from $53.4 million recorded in Q2 2025.
  • Over the past 5 years, Recursion Pharmaceuticals' Operating Leases peaked at $89.5 million during Q3 2024, and registered a low of $44.4 million during Q4 2022.
  • Moreover, its 4-year median value for Operating Leases was $51.4 million (2022), whereas its average is $57.1 million.
  • Its Operating Leases has fluctuated over the past 5 years, first skyrocketed by 8031.62% in 2024, then crashed by 4412.53% in 2025.
  • Over the past 4 years, Recursion Pharmaceuticals' Operating Leases (Quarter) stood at $44.4 million in 2022, then increased by 11.5% to $49.5 million in 2023, then skyrocketed by 35.78% to $67.2 million in 2024, then decreased by 25.61% to $50.0 million in 2025.
  • Its Operating Leases was $50.0 million in Q3 2025, compared to $53.4 million in Q2 2025 and $56.0 million in Q1 2025.